Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer

Authors: Linna Su, Xiangqiang Liu, Na Chai, Lifen Lv, Rui Wang, Xiaosa Li, Yongzhan Nie, Yongquan Shi, Daiming Fan

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

FOXO4, a member of the FOXO family of transcription factors, is currently the focus of intense study. Its role and function in gastric cancer have not been fully elucidated. The present study was aimed to investigate the expression profile of FOXO4 in gastric cancer and the effect of FOXO4 on cancer cell growth and metastasis.

Methods

Immunohistochemistry, Western blotting and qRT-PCR were performed to detect the FOXO4 expression in gastric cancer cells and tissues. Cell biological assays, subcutaneous tumorigenicity and tail vein metastatic assay in combination with lentivirus construction were performed to detect the impact of FOXO4 to gastric cancer in proliferation and metastasis in vitro and in vivo. Confocal and qRT-PCR were performed to explore the mechanisms.

Results

We found that the expression of FOXO4 was decreased significantly in most gastric cancer tissues and in various human gastric cancer cell lines. Up-regulating FOXO4 inhibited the growth and metastasis of gastric cancer cell lines in vitro and led to dramatic attenuation of tumor growth, and liver and lung metastasis in vivo, whereas down-regulating FOXO4 with specific siRNAs promoted the growth and metastasis of gastric cancer cell lines. Furthermore, we found that up-regulating FOXO4 could induce significant G1 arrest and S phase reduction and down-regulation of the expression of vimentin.

Conclusion

Our data suggest that loss of FOXO4 expression contributes to gastric cancer growth and metastasis, and it may serve as a potential therapeutic target for gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004, 21 (8): 755-764.CrossRefPubMed
3.
Kajita Y, Kato T, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J: The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PloS one. 2013, 8 (1): e49709-10.1371/journal.pone.0049709.CrossRefPubMedPubMedCentral
4.
Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu F, Ethier SP, Miller F, Wu G: Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011, 71 (4): 1292-1301. 10.1158/0008-5472.CAN-10-2825.CrossRefPubMedPubMedCentral
5.
Atreya I, Schimanski CC, Becker C, Wirtz S, Dornhoff H, Schnurer E, Berger MR, Galle PR, Herr W, Neurath MF: The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut. 2007, 56 (11): 1572-1578. 10.1136/gut.2006.117812.CrossRefPubMedPubMedCentral
6.
Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Frohling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011, 146 (5): 697-708. 10.1016/j.cell.2011.07.032.CrossRefPubMed
7.
Daitoku H, Sakamaki J, Fukamizu A: Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta. 2011, 1813 (11): 1954-1960. 10.1016/j.bbamcr.2011.03.001.CrossRefPubMed
8.
Maiese K, Chong ZZ, Shang YC: OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008, 14 (5): 219-227. 10.1016/j.molmed.2008.03.002.CrossRefPubMedPubMedCentral
9.
van der Vos KE, Coffer PJ: FOXO-binding partners: it takes two to tango. Oncogene. 2008, 27 (16): 2289-2299. 10.1038/onc.2008.22.CrossRefPubMed
10.
Watroba M, Maslinska D, Maslinski S: Current overview of functions of FoxO proteins, with special regards to cellular homeostasis, cell response to stress, as well as inflammation and aging. Adv Med Sci. 2012, 57 (2): 183-195. 10.2478/v10039-012-0039-1.CrossRefPubMed
11.
Zhu J, Mounzih K, Chehab EF, Mitro N, Saez E, Chehab FF: Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake. J Lipid Res. 2010, 51 (6): 1312-1324. 10.1194/jlr.M001586.CrossRefPubMedPubMedCentral
12.
Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, Hu H, Nie Y, Wang X, Wu K, Jin H, Fan D: MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis. 2011, 32 (12): 1798-1805. 10.1093/carcin/bgr213.CrossRefPubMed
13.
Zhang Y, Gan B, Liu D, Paik JH: FoxO family members in cancer. Cancer Biol Ther. 2011, 12 (4): 253-259. 10.4161/cbt.12.4.15954.CrossRefPubMed
14.
Zhang X, Tang N, Hadden TJ, Rishi AK: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011, 1813 (11): 1978-1986. 10.1016/j.bbamcr.2011.03.010.CrossRefPubMed
15.
Kleindorp R, Flachsbart F, Puca AA, Malovini A, Schreiber S, Nebel A: Candidate gene study of FOXO1, FOXO4, and FOXO6 reveals no association with human longevity in Germans. Aging Cell. 2011, 10 (4): 622-628. 10.1111/j.1474-9726.2011.00698.x.CrossRefPubMed
16.
Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R, Jilka RL, Weinstein RS, O'Brien CA, Manolagas SC, Almeida M: FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest. 2013, 123 (8): 3409-3419. 10.1172/JCI68049.CrossRefPubMedPubMedCentral
17.
Bullock MD, Sayan AE, Packham GK, Mirnezami AH: MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell. 2012, 104 (1): 3-12. 10.1111/boc.201100115.CrossRefPubMed
18.
Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Canc. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRef
19.
Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, Brabletz T: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006, 131 (3): 830-840. 10.1053/j.gastro.2006.06.016.CrossRefPubMed
Metadata
Title
The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer
Authors
Linna Su
Xiangqiang Liu
Na Chai
Lifen Lv
Rui Wang
Xiaosa Li
Yongzhan Nie
Yongquan Shi
Daiming Fan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-378

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The effects of psychological interventions on depression and anxiety among Chinese adults with cancer: a meta-analysis of randomized controlled studies

Research article

NILCO biomarkers in breast cancer from Chinese patients

Research article

Pattern of use of radiotherapy for lung cancer: a descriptive study

Study protocol

Study protocol: a randomised controlled trial of a theory-based online intervention to improve sun safety among Australian adults

Research article

COUP-TFI modifies CXCL12 and CXCR4 expression by activating EGF signaling and stimulates breast cancer cell migration

Research article

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits